Blood Platelet Disorders  >>  luminespib (AUY922)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
luminespib (AUY922) / Ligand
NCT01668173: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Terminated
2
7
US
AUY922
Memorial Sloan Kettering Cancer Center, Novartis
Myeloproliferative Neoplasms
05/15
05/15

Download Options